PathoGene is developing an automated in vitro diagnostic device that detects and identifies 1,400 human pathogens and antimicrobial resistance genes using a single test panel. This technology provides results 12 times faster than traditional methods, enabling healthcare providers to make timely treatment decisions and improve patient outcomes.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional pathogen identification methods are often slow and require multiple tests to detect different types of infections, leading to delays in diagnosis and appropriate treatment. This can result in increased morbidity, mortality, and healthcare costs due to ineffective initial therapies and prolonged hospital stays.
Solution
PathoGene is developing an automated in vitro diagnostic platform capable of detecting and identifying approximately 1,400 human pathogens and antimicrobial resistance genes from a single sample. The system utilizes a comprehensive test panel to simultaneously screen for viral, bacterial, fungal, and parasitic infections, as well as genetic markers associated with antibiotic resistance. By consolidating multiple tests into a single assay, PathoGene's technology significantly reduces the time required to obtain actionable results, enabling clinicians to make more informed and timely treatment decisions. The platform aims to improve patient outcomes, reduce the spread of antimicrobial resistance, and optimize resource utilization in healthcare settings.
Target Audience
The primary target audience includes hospitals, independent diagnostic testing facilities, and research institutes seeking to improve pathogen identification and antimicrobial stewardship.
Features
- Single test panel for the detection of 1,400 pathogens, including viral, bacterial, fungal, and parasitic agents.
- Identification of antimicrobial resistance genes to guide appropriate antibiotic selection.
- Automated in vitro diagnostic platform for streamlined workflow and reduced hands-on time.
- Rapid results, providing actionable information 12 times faster than traditional methods.
- Affordable test pricing.